Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

被引：0
|
作者：
Xiaoying Gu
Su Zhang
Xuejiao Yang
Tao Guan
Zhenyu Hou
Manqing Cao
Huikai Li
Ti Zhang
机构：
[1] Tianjin Medical University Cancer Institute and Hospital,Department of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[2] National Clinical Research Center for Cancer,Department of Gynecologic Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[3] Tianjin Medical University Cancer Institute and Hospital,Present Address: Department of Anesthesiology
[4] National Clinical Research Center for Cancer,Department of Breast Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[5] The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Present Address: Department of Hepatic Surgery
[6] Tianjin Medical University Cancer Institute and Hospital,undefined
[7] National Clinical Research Center for Cancer,undefined
[8] Fudan University Shanghai Cancer Center,undefined
[9] Shanghai Medical College,undefined
[10] Fudan University,undefined
来源：
BMC Gastroenterology | / 22卷
关键词：
Apatinib; Anti-angiogenesis therapy; Adverse Events; Hepatocellular Carcinoma; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Apatinib as an alternative therapy for advanced hepatocellular carcinoma
    Zhang, Xi-Hao
    Cao, Man-Qing
    Li, Xiu-Xiu
    Zhang, Ti
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (10) : 766 - 774
  • [22] Letter regarding "Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma"
    Wang, Yinhan
    Huang, Yongfa
    Yang, Huayu
    Mao, Yilei
    LIVER CANCER, 2023, 12 (01) : 85 - 86
  • [23] Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma
    Furuse, J
    Ishii, H
    Nagase, M
    Kawashima, M
    Ogino, T
    Yoshino, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (10) : 1512 - 1518
  • [24] Apatinib as an alternative therapy for advanced hepatocellular carcinoma
    Xi-Hao Zhang
    Man-Qing Cao
    Xiu-Xiu Li
    Ti Zhang
    World Journal of Hepatology, 2020, 12 (10) : 766 - 774
  • [25] Parental reporting of adverse drug events and other drug-related problems in children in Finland
    L. Lindell-Osuagwu
    K. Sepponen
    S. Farooqui
    H. Kokki
    K. Hämeen-Anttila
    K. Vainio
    European Journal of Clinical Pharmacology, 2013, 69 : 985 - 994
  • [26] Parental reporting of adverse drug events and other drug-related problems in children in Finland
    Lindell-Osuagwu, L.
    Sepponen, K.
    Farooqui, S.
    Kokki, H.
    Hameen-Anttila, K.
    Vainio, K.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 985 - 994
  • [27] Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma
    Hoshida, Y
    Shiratori, Y
    Koike, Y
    Obi, S
    Hamamura, K
    Teratani, T
    Shiina, S
    Omata, M
    HEPATO-GASTROENTEROLOGY, 2002, 49 (44) : 451 - 455
  • [28] The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
    Yang, Zeran
    Chen, Guang
    Cui, Ye
    Xiao, Guowen
    Su, Tianhao
    Yu, Jianan
    Zhang, Zhiyuan
    Han, Yanjing
    Yang, Kailan
    Jin, Long
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 321 - 327
  • [29] Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study
    Yu, Wen-Chang
    Zhang, Kong-Zhi
    Chen, Shi-Guang
    Liu, Wei-Fu
    MEDICINE, 2018, 97 (03)
  • [30] Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department
    Hohl, CM
    Dankoff, J
    Colacone, A
    Afilalo, M
    ANNALS OF EMERGENCY MEDICINE, 2001, 38 (06) : 666 - 671
12345